TX000045
Sponsors
Tectonic Therapeutic Inc., Tectonic Operating Company Inc., Tectonic Operating Company, Inc.
Conditions
Hypertension, PulmonaryLung Diseases, InterstitialPulmonary HypertensionPulmonary hypertension secondary to interstitial lung disease
Phase 2
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
RecruitingCTIS2024-514283-40-00
Start: 2024-12-19Target: 181Updated: 2025-12-19
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
RecruitingNCT07473700
Start: 2026-10-01End: 2027-12-11Target: 25Updated: 2026-09-08
An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease
Not yet recruitingCTIS2026-525810-80-00
Target: 3Updated: 2026-07-17